VIA Pharmaceuticals

VIAP

Medical - Pharmaceuticals · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$10,279

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+312.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 5.0M (2006) → 20.5M (2010)

Winston Score History

The full picture

VIA Pharmaceuticals is a small pharmaceutical company focused on developing drugs to treat cardiovascular diseases, particularly conditions related to abnormal heart rhythms and related complications. The company works on experimental medicines that have not yet reached widespread commercial use, meaning it is still in the research and development stage rather than selling products at scale.

The company generates little to no revenue at this stage, which is typical for early-phase drug developers that spend most of their money on clinical trials and research before any product is approved. VIA Pharmaceuticals operates primarily in the United States and has a very small market presence. Because it has no approved products generating consistent sales, its main risk is running out of cash before successfully advancing a drug through clinical trials and regulatory approval — a challenge that affects most small biotech and pharma companies at this stage of development.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+43.2% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$2M/ year

↓ Declining (-70% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

1.7%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$84,001 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

VIA Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial